Abstract
After looking at data used to support treatment of women with slightly lowered bone mineral density, Pablo Alonso-Coello and colleagues argue thatproponents have overstated the benefits and underplayed the harms
MeSH terms
-
Bone Density Conservation Agents / adverse effects
-
Bone Density Conservation Agents / therapeutic use*
-
Conflict of Interest
-
Female
-
Humans
-
Marketing of Health Services
-
Meta-Analysis as Topic
-
Osteoporosis / drug therapy*
-
Risk Assessment
-
Risk Factors
Substances
-
Bone Density Conservation Agents